The low cost, ease of immobilization onto supports, and stability of dye-ligands have made these binding agents popular in affinity separations, as demonstrated in Figure 6, and especially for large-scale processes [126,127]
Disclosures: Anish Reddy: Nothing to Disclose, Christopher Bowlus: Calliditas: Grant/Research Support, ChemoMab: Grant/Research Support, ChemoMab: Consultant, COUR Phamaceuticals: Grant/Research Support, Cymabay: Grant/Research Support, Cymabay: Consultant, Cymabay: Consultant, Gilead: Grant/Research Support, GSK Pharmaceuticals: Grant/Research Support, GSK Pharmaceuticals: Consultant, Hanmi: Grant/Research Support, Intercept: Grant/Research Support, Invea Therapeutics: Consultant, Ipsen: Grant/Research Support, Ipsen: Consultant, Mirum: Grant/Research Support, NGM Bio: Consultant, Novartis: Grant/Research Support, Novo Nordisk: Grant/Research Support, Pliant Therapeutics: Grant/Research Support, Pliant Therapeutics: Consultant, Viking Therapeutics: Grant/Research Support, Zydus Therapeutics: Grant/Research Support, Marlyn Mayo: CymaBay: Grant/Research Support, CymaBay: Consultant, GSK: Grant/Research Support, GSK: Consultant, Intercept: Grant/Research Support, IntraSana: Consultant, Ipsen: Grant/Research Support, Ipsen: Consultant, Mallinckrodt: Grant/Research Support, Mallinckrodt: Consultant, Mirum: Grant/Research Support, Target RWE: Grant/Research Support, Elizabeth Carey: Nothing to Disclose, Andrea Mospan: Nothing to Disclose, Aparna Goel: Nothing to Disclose, Cynthia Levy: Cymabay: Grant/Research Support, Cymabay: Consultant, Intercept: Grant/Research Support, Intercept: Consultant, Calliditas: Grant/Research Support, Calliditas: Consultant, GSK: Consultant, GSK: Grant/Research Support, Ipsen: Grant/Research Support, Ipsen: Consultant, Mirum: Grant/Research Support, Mirum: Consultant, Zydus: Grant/Research Support, Gilead: Grant/Research Support, Gilead: Consultant, Escient: Grant/Research Support, Kowa: Grant/Research Support, Kowa: Consultant, Genfit: Grant/Research Support, COur: Advisor, Chemomab: Consultant 2386 DIABETES IS ASSOCIATED WITH POOR LIVER RELATED OUTCOMES IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS Shreeya Thussu 1 Spyridon Zouridis 2 Kamran Qureshi 3 , 1 Saint Louis University School of Medicine, 2 Saint Louis University School of Medicin, 3 Saint Louis University Background: Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease estimated to affect 14.6 per 100,000 persons worldwide, predominantly females
People either use it and its magic or use it and it does nothing
10.1099/00221287-133-10-2787 Microbiology 32 OchiK.KandalaJ
Temporary Implantable Nitinol Device ( iTind ): A temporary implantable device to relieve bladder outlet obstruction
